A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).
Small Cell Lung Carcinoma
DRUG: BMS-986489
Number of participants with adverse events (AEs), Up to 12 months after last participant's first treatment|Number of participants with Serious AEs (SAEs), Up to 12 months after last participant's first treatment|Number of participants with AEs leading to discontinuation of study treatment, Up to 12 months after last participant's first treatment|Number of participants with select AEs, Up to 12 months after last participant's first treatment|Number of participants with immune-mediated AEs (IMAEs), Up to 12 months after last participant's first treatment|Number of deaths, Up to 12 months after last participant's first treatment|Number of participants with laboratory abnormalities, Up to 12 months after last participant's first treatment|Maximum observed concentration (Cmax) for BMS-986012, Up to 12 months after last participant's first treatment|Time of maximum observed concentration (Tmax) for BMS-986012, Up to 12 months after last participant's first treatment|Trough observed plasma concentration (Ctrough) for BMS-986012, Up to 12 months after last participant's first treatment|Concentration at the end of a dosing interval (Ctau) for BMS-986012, Up to 12 months after last participant's first treatment|Average concentration over a dosing interval ([AUC(TAU)/TAU]) (Cavg(TAU)) for BMS-986012, Up to 12 months after last participant's first treatment|Area under the concentration-time curve within one dosing interval (AUC(TAU)) for BMS-986012, Up to 12 months after last participant's first treatment|Total body clearance (CLT) for BMS-986012, Up to 12 months after last participant's first treatment|Observed concentration at end of infusion (Ceoi) for BMS-986012, Up to 12 months after last participant's first treatment
Number of participants with anti-drug antibodies (ADAs) to BMS-986012, Up to 12 months after last participant's first treatment|Number of participants with ADAs to nivolumab, Up to 12 months after last participant's first treatment|Ctrough for nivolumab, Up to 12 months after last participant's first treatment|Ceoi for nivolumab, Up to 12 months after last participant's first treatment|Overall Response (OR), Achievement of best response of complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, assessed by the investigator., Up to 12 months after last participant's first treatment|Disease Control (DC), Achievement of best response of CR or PR or stable disease (SD) using RECIST v1.1 criteria, assessed by the investigator., Up to 12 months after last participant's first treatment|Duration of Response (DOR), Time from first response (CR or PR) to first documented disease progression by investigator or death, whichever occurs first. For participants who did not have an event, the DOR will be censored on the date of their last tumor assessment., Up to 12 months after last participant's first treatment
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).